SEARCH

SEARCH BY CITATION

References

  • Aizenstein H. J., Nebes R. D., Saxton J. A. et al. (2008) Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch. Neurol. 65, 15091517.
  • Backstrom J. R., Lim G. P., Cullen M. J. and Tokes Z. A. (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1–40). J. Neurosci. 16, 79107919.
  • Basak J. M., Kim J., Pyatkivskyy Y., Wildsmith K. R., Jiang H., Parsadanian M., Patterson B. W., Bateman R. J. and Holtzman D. M. (2012) Measurement of apolipoprotein E and amyloid beta clearance rates in the mouse brain using bolus stable isotope labeling. Mol. Neurodegener. 7, 14.
  • Bell R. D., Winkler E. A., Singh I. et al. (2012) Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512516.
  • Bove P. F., Wesley U. V., Greul A. K., Hristova M., Dostmann W. R. and van der Vliet A. (2007) Nitric oxide promotes airway epithelial wound repair through enhanced activation of MMP-9. Am. J. Respir. Cell Mol. Biol. 36, 138146.
  • Candelario-Jalil E., Yang Y. and Rosenberg G. A. (2009) Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158, 983994.
  • Colton C. A. and Wilcock D. M. (2010) Assessing activation states in microglia. CNS Neurol. Disord. Drug Targets 9, 174191.
  • Colton C. A., Keri J. E., Chen W. T. and Monsky W. L. (1993) Protease production by cultured microglia: substrate gel analysis and immobilized matrix degradation. J. Neurosci. Res. 35, 297304.
  • Colton C., Wilt S., Gilbert D., Chernyshev O., Snell J. and Dubois-Dalcq M. (1996) Species differences in the generation of reactive oxygen species by microglia. Mol. Chem. Neuropathol. 28, 1520.
  • Crocker S. J., Frausto R. F., Whitton J. L. and Milner R. (2008) A novel method to establish microglia-free astrocyte cultures: comparison of matrix metalloproteinase expression profiles in pure cultures of astrocytes and microglia. Glia 56, 11871198.
  • Davies K. M., Wink D. A., Saavedra J. E. and Keefer L. K. (2001) Chemistry of the diazeniumdiolates. 2. Kinetics and mechanism of dissociation to nitric oxide in aqueous solution. J. Am. Chem. Soc. 123, 54735481.
  • Davis J., Xu F., Deane R., Romanov G., Previti M. L., Zeigler K., Zlokovic B. V. and Van Nostrand W. E. (2004) Early-onset and robust cerebral microvascular accumulation of amyloid beta-protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant form of amyloid beta-protein precursor. J. Biol. Chem. 279, 2029620306.
  • Death A. K., Nakhla S., McGrath K. C., Martell S., Yue D. K., Jessup W. and Celermajer D. S. (2002) Nitroglycerin upregulates matrix metalloproteinase expression by human macrophages. J. Am. Coll. Cardiol. 39, 19431950.
  • Gandy S. (2005) The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Investig. 115, 11211129.
  • Ganster R. W., Taylor B. S., Shao L. and Geller D. A. (2001) Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc. Natl Acad. Sci. USA 98, 86388643.
  • Gardner J. and Ghorpade A. (2003) Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system. J. Neurosci. Res. 74, 801806.
  • George S. J. and Johnson J. L. (2010) In situ zymography. Methods Mol. Biol. 622, 271277.
  • Glenner G. G. (1989) The pathobiology of Alzheimer's disease. Annu. Rev. Med. 40, 4551.
  • Gordon S. and Taylor P. R. (2005) Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5, 953964.
  • Gottschall P. E. (1996) Beta-Amyloid induction of gelatinase B secretion in cultured microglia: inhibition by dexamethasone and indomethacin. NeuroReport 7, 30773080.
  • Gottschall P. E. and Yu X. (1995) Cytokines regulate gelatinase A and B (matrix metalloproteinase 2 and 9) activity in cultured rat astrocytes. J. Neurochem. 64, 15131520.
  • Gottschall P. E., Yu X. and Bing B. (1995) Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J. Neurosci. Res. 42, 335342.
  • Guo Z., Shao L., Zheng L., Du Q., Li P., John B. and Geller D. A. (2012) miRNA-939 regulates human inducible nitric oxide synthase posttranscriptional gene expression in human hepatocytes. Proc. Natl Acad. Sci. USA 109, 58265831.
  • Hartell N. A. and Suh Y. H. (2000) Peptide fragments of beta-amyloid precursor protein: effects on parallel fiber-Purkinje cell synaptic transmission in rat cerebellum. J. Neurochem. 74, 11121121.
  • Hawkes C. A., Hartig W., Kacza J., Schliebs R., Weller R. O., Nicoll J. A. and Carare R. O. (2011) Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. 121, 431443.
  • Huang Y., Potter R., Sigurdson W. et al. (2012) Effects of age and amyloid deposition on Abeta dynamics in the human central nervous system. Arch. Neurol. 69, 5158.
  • Kang J. E., Lim M. M., Bateman R. J., Lee J. J., Smyth L. P., Cirrito J. R., Fujiki N., Nishino S. and Holtzman D. M. (2009) Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326, 10051007.
  • Kleiner D. E. and Stetler-Stevenson W. G. (1994) Quantitative zymography: detection of picogram quantities of gelatinases. Anal. Biochem. 218, 325329.
  • Koronyo-Hamaoui M., Ko M. K., Koronyo Y. et al. (2009) Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J. Neurochem. 111, 14091424.
  • Krishnatry A. S., Fung S. M., Brazeau D. A., Soda D. and Fung H. L. (2011a) Nitroglycerin alters matrix remodeling proteins in THP-1 human macrophages and plasma metalloproteinase activity in rats. Nitric Oxide 24, 6676.
  • Krishnatry A. S., Kamei T., Wang H., Qu J. and Fung H. L. (2011b) Identification of nitroglycerin-induced cysteine modifications of pro-matrix metalloproteinase-9. Rapid Commun. Mass Spectrom. 25, 22912298.
  • Laubach V. E., Foley P. L., Shockey K. S., Tribble C. G. and Kron I. L. (1998) Protective roles of nitric oxide and testosterone in endotoxemia: evidence from NOS-2-deficient mice. Am. J. Physiol. 275, H22112218.
  • LeVine H., 3rd (1999) Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol. 309, 274284.
  • Liao M. C. and Van Nostrand W. E. (2010) Degradation of soluble and fibrillar amyloid beta-protein by matrix metalloproteinase (MT1-MMP) in vitro. Biochemistry 49, 11271136.
  • Liu W., Rosenberg G. A. and Liu K. J. (2006) AUF-1 mediates inhibition by nitric oxide of lipopolysaccharide-induced matrix metalloproteinase-9 expression in cultured astrocytes. J. Neurosci. Res. 84, 360369.
  • Livak K. J. and Schmittgen T. D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402408.
  • Ma Q. F., Hu J., Wu W. H., Liu H. D., Du J. T., Fu Y., Wu Y. W., Lei P., Zhao Y. F. and Li Y. M. (2006) Characterization of copper binding to the peptide amyloid-beta(1–16) associated with Alzheimer's disease. Biopolymers 83, 2031.
  • Miners J. S., Baig S., Palmer J., Palmer L. E., Kehoe P. G. and Love S. (2008) Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 18, 240252.
  • Miners J. S., Baig S., Tayler H., Kehoe P. G. and Love S. (2009) Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J. Neuropathol. Exp. Neurol. 68, 902914.
  • Miners J. S., Barua N., Kehoe P. G., Gill S. and Love S. (2011) Abeta-degrading enzymes: potential for treatment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 70, 944959.
  • Morgan D. (2006) Immunotherapy for Alzheimer's disease. J. Alzheimers Dis. 9, 425432.
  • Mufson E. J., Binder L., Counts S. E., DeKosky S. T., de Toledo-Morrell L., Ginsberg S. D., Ikonomovic M. D., Perez S. E. and Scheff S. W. (2012) Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol. 123, 1330.
  • Van Muiswinkel F. L., Raupp S. F., de Vos N. M., Smits H. A., Verhoef J., Eikelenboom P. and Nottet H. S. (1999) The amino-terminus of the amyloid-beta protein is critical for the cellular binding and consequent activation of the respiratory burst of human macrophages. J. Neuroimmunol. 96, 121130.
  • Patruno A., Pesce M., Marrone A., Speranza L., Grilli A., De Lutiis M. A., Felaco M. and Reale M. (2012) Activity of matrix metallo proteinases (MMPs) and the tissue inhibitor of MMP (TIMP)-1 in electromagnetic field-exposed THP-1 cells. J. Cell. Physiol. 227, 27672774.
  • Qiu W. Q., Ye Z., Kholodenko D., Seubert P. and Selkoe D. J. (1997) Degradation of amyloid beta-protein by a metalloprotease secreted by microglia and other neural and non-neural cells. J. Biol. Chem. 272, 66416646.
  • Ridnour L. A., Windhausen A. N., Isenberg J. S., Yeung N., Thomas D. D., Vitek M. P., Roberts D. D. and Wink D. A. (2007) Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc. Natl Acad. Sci. USA 104, 1689816903.
  • Ridnour L. A., Barasch K. M., Windhausen A. N. et al. (2012) Nitric Oxide Synthase and Breast Cancer: Role of TIMP-1 in NO-mediated Akt Activation. PLoS One 7, 115.
  • Roher A. E., Kasunic T. C., Woods A. S., Cotter R. J., Ball M. J. and Fridman R. (1994) Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochem. Biophys. Res. Commun. 205, 17551761.
  • Shin C. Y., Lee W. J., Choi J. W., Choi M. S., Ryu J. R., Oh S. J., Cheong J. H., Choi E. Y. and Ko K. H. (2007) Down-regulation of matrix metalloproteinase-9 expression by nitric oxide in lipopolysaccharide-stimulated rat primary astrocytes. Nitric Oxide 16, 425432.
  • Van den Steen P. E., Dubois B., Nelissen I., Rudd P. M., Dwek R. A. and Opdenakker G. (2002) Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37, 375536.
  • De Strooper B. (2010) Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev. 90, 465494.
  • Tanzi R. E., Moir R. D. and Wagner S. L. (2004) Clearance of Alzheimer's abeta peptide: the many roads to perdition. Neuron 43, 605608.
  • Thomas D. D., Miranda K. M., Espey M. G. et al. (2002) Guide for the use of nitric oxide (NO) donors as probes of the chemistry of NO and related redox species in biological systems. Methods Enzymol. 359, 84105.
  • Vellas B., Black R., Thal L. J., Fox N. C., Daniels M., McLennan G., Tompkins C., Leibman C., Pomfret M. and Grundman M. (2009) Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr. Alzheimer Res. 6, 144151.
  • Verdile G., Fuller S., Atwood C. S., Laws S. M., Gandy S. E. and Martins R. N. (2004) The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught? Pharmacol. Res. 50, 397409.
  • Van Vickle G. D., Esh C. L., Daugs I. D. et al. (2008) Tg-SwDI transgenic mice exhibit novel alterations in AbetaPP processing, Abeta degradation, and resilient amyloid angiopathy. Am. J. Pathol. 173, 483493.
  • Wang H. H., Hsieh H. L. and Yang C. M. (2011) Nitric oxide production by endothelin-1 enhances astrocytic migration via the tyrosine nitration of matrix metalloproteinase-9. J. Cell. Physiol. 226, 22442256.
  • Wei L., Gravitt P. E., Song H., Maldonado A. M. and Ozbun M. A. (2009) Nitric oxide induces early viral transcription coincident with increased DNA damage and mutation rates in human papillomavirus-infected cells. Cancer Res. 69, 48784884.
  • Weinberg J. B., Misukonis M. A., Shami P. J. et al. (1995) Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. Blood 86, 11841195.
  • Weiss J. M., Ridnour L. A., Back T. et al. (2010) Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J. Exp. Med. 207, 24552467.
  • Weller R. O., Subash M., Preston S. D., Mazanti I. and Carare R. O. (2008) Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol. 18, 253266.
  • Wilcock D. M., Lewis M. R., Van Nostrand W. E., Davis J., Previti M. L., Gharkholonarehe N., Vitek M. P. and Colton C. A. (2008) Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci. 28, 15371545.
  • Wilcock D. M., Morgan D., Gordon M. N., Taylor T. L., Ridnour L. A., Wink D. A. and Colton C. A. (2011) Activation of matrix metalloproteinases following anti-Abeta immunotherapy; implications for microhemorrhage occurrence. J. Neuroinflammation 8, 115.
  • Yan P., Hu X., Song H. et al. (2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281, 2456624574.
  • Yin K. J., Cirrito J. R., Yan P. et al. (2006) Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-beta peptide catabolism. J. Neurosci. 26, 1093910948.
  • Zhang J. W. and Gottschall P. E. (1997) Zymographic measurement of gelatinase activity in brain tissue after detergent extraction and affinity-support purification. J. Neurosci. Methods 76, 1520.
  • del Zoppo G. J. (2010) The neurovascular unit, matrix proteases, and innate inflammation. Ann. N. Y. Acad. Sci. 1207, 4649.